Patrick Holt is recorded as CEO and Board Member at Amarin Corp Plcuk (AMRN) since July 18, 2023. Amarin Corp Plcuk reported in an 8-K filed June 4, 2024 that Patrick Holt resigned as President and Chief Executive Officer, effective June 3, 2024. Amarin Corp Plcuk reported in an 8-K filed July 20, 2023 that Patrick Holt was appointed member of the Amarin board of directors, effective July 18, 2023. Amarin Corp Plcuk reported in an 8-K filed July 20, 2023 that Patrick Holt was appointed President and Chief Executive Officer (and principal executive officer), effective July 18, 2023. Equibles holds 5 filed executive changes naming Patrick Holt; each is listed under recent activity with its source filing. The proxy statement of Amarin Corp Plcuk reports total compensation of $2,143,683 for Patrick Holt in fiscal 2023, including a base salary of $306,779. Patrick Holt has spoken on 3 earnings calls across 1 company, most recently for Amarin Corp Plcuk on May 1, 2024. Amarin Corp Plcuk is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Amarin Corp Plcuk includes Aaron D. Berg (CEO), Odysseas D. Kostas (Chairman), Per Wold-Olsen (Chairman) and 7 others.
“On June 3, 2024, Patrick Holt notified Amarin Corporation plc (the "Company") of his decision to voluntarily resign as President and Chief Executive Officer of the Company, effective immediately.”
Amarin Corp Plcuk Form 8-K, filed June 4, 2024
· Read the filing
“In addition, Mr. Holt was also appointed as a member of the Amarin board of directors (the “Board”), effective as of the CEO Start Date.”
Amarin Corp Plcuk Form 8-K, filed July 20, 2023
· Read the filing
Patrick Holt on recent calls
“Our team at Amarin is focused on making progress to enhance the value of our business and maximize the patient uptake of VASCEPA/VAZKEPA. We firmly believe this focus is the best plan for Amarin and positions us strongly for the future.”
“Before we review our 2023 highlights and our 2024 priorities, I want to take a moment to reflect on our strategy at Amarin. Every day, our team is focused on driving operational momentum to maximize the patient uptake of VASCEPA/VAZKEPA.”
